James O Armitage MD FACP FRCP and Bertrand Coiffier MD PhD on Managing Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multicenter Phase II Study Report,” presented by Jia Ruan, MD, PhD.

Leukemia

Linda J. Burns, MD

Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380, “T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long-Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD.

Time: 1:26

Myelodysplastic Syndromes

Leukemia

Alan F. List, MD

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Label, Phase II, Dose-Finding Study of Sotatercept (ACE-011) in Patients With Low or Intermediate-1–Risk Myelodysplastic Syndromes or Nonproliferative Chronic Myelomonocytic Leukemia and Anemia Requiring Transfusion,” presented by Rami S. Komrokji, MD.

Leukemia

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Hagop M. Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, discuss the diagnosis and genetics of ALL, differences in treating younger and older patients, and the latest data on the use of tyrosine kinase inhibitors, monoclonal antibodies, and CAR T cells.

Lymphoma

Bertrand Coiffier, MD

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 504, “Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association With CHOP in Patients With Peripheral T-Cell Lymphoma (PTCL)” presented by Jehan Dupuis, MD.

Time: 1:53

James O. Armitage, MD, FACP, FRCP, and Bertrand Coiffier, MD, PhD, on Managing Lymphoma: The French Perspective

Related Videos

Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

Linda J. Burns, MD, on CAR T-Cell Therapy in ALL

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

James O. Armitage, MD, FACP, FRCP, and Hagop M. Kantarjian, MD, on Advances in the Treatment of ALL

Bertrand Coiffier, MD, PhD, on the RO-CHOP Study

Neoadjuvant Osimertinib in the Perioperative Setting for Resectable EGFR-Mutated NSCLC

Can Autoimmune Diseases Increase the Risk of Digestive System Cancer

Are Postmastectomy Implant-Based Breast Reconstructions Associated With Lymphomas of the Breast?

John Byrd Named UPMC Hillman Cancer Center Director

OHSU Knight Cancer Institute Receives 2 Billion Commitment From Phil and Penny Knight